Following from the success of T-DM1, T-DXd (fam-trastuzumab-deruxtecan-nxki [Enhertu]) was developed and approved for unresectable or metastatic HER2+ breast cancer patients who have previously received two or more HER2 targeting treatments [59]. This evidence concerns the gene ERBB2 and breast carcinoma.